Bristol-Myers Squibb Services Unlimited Company

Oncology

The sponsor’s oncology portfolio spans non-small cell lung cancer, melanoma, urothelial cancer, breast cancer, colorectal cancer, pancreatic ductal adenocarcinoma, gastric and gastroesophageal cancers, hepatocellular carcinoma, renal cell carcinoma, ovarian cancer, bladder cancer, and myelofibrosis. It also includes studies in acute myeloid leukemia, myelodysplastic syndrome, primary central nervous system lymphoma, and other advanced solid tumors.

  • Immuno-oncology
  • Targeted therapy
  • Metastatic cancer
  • Hematologic malignancies
  • Perioperative and first-line cancer treatment

Research activity includes treatment of EGFR-mutated and KRAS G12C-mutant disease, as well as platinum-resistant and unresectable cancer settings.

Autoimmune and inflammatory disease

Clinical research in immune-mediated disease centers on systemic lupus erythematosus, cutaneous lupus erythematosus, psoriatic arthritis, plaque psoriasis, rheumatoid arthritis, Sjögren’s syndrome, systemic sclerosis, idiopathic inflammatory myopathy, ulcerative colitis, and atopic dermatitis.

  • Systemic lupus erythematosus
  • Psoriatic arthritis
  • Psoriasis
  • Inflammatory bowel disease
  • Connective tissue disease

Additional work extends to juvenile psoriatic arthritis and pediatric immune-mediated conditions.

Neurology and psychiatry

The sponsor funds trials in Alzheimer’s disease, including early and mild to moderate stages, with associated agitation and psychosis. Its neuroscience portfolio also includes bipolar I disorder, mania, schizophrenia, and relapsing remitting multiple sclerosis.

  • Alzheimer’s disease
  • Bipolar I disorder
  • Schizophrenia
  • Multiple sclerosis
  • Neuropsychiatric symptoms

Research also addresses primary central nervous system lymphoma within the broader neuro-oncology landscape.

Pulmonary and cardiovascular disease

Respiratory and cardiometabolic studies include idiopathic pulmonary fibrosis, progressive pulmonary fibrosis, and heart failure with preserved ejection fraction. Cardiovascular research also covers symptomatic obstructive hypertrophic cardiomyopathy.

  • Interstitial lung disease
  • Pulmonary fibrosis
  • Heart failure
  • Hypertrophic cardiomyopathy

These programs reflect interest in chronic cardiopulmonary disorders with significant unmet treatment need.

Hematology, transplantation, and rare disease

Additional clinical work includes sickle cell disease, renal transplantation, and adolescent renal allograft care, alongside studies in myelofibrosis and other hematologic disorders. The portfolio also extends to urothelial carcinoma and solid malignancies with high-risk or refractory features.

  • Sickle cell disease
  • Renal transplantation
  • Myelofibrosis
  • Urothelial carcinoma

Research activity in these areas spans both chronic disease management and oncology-linked rare conditions.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • Study on Deucravacitinib and Apremilast for Patients with Active Psoriatic Arthritis New to Biologic Treatments or Previously on TNFα Inhibitors

    Not recruiting

    3 1 1
    Belgium Czechia Germany Hungary Poland Spain
  • Study on Deucravacitinib for Patients with Active Psoriatic Arthritis New to Biologic Treatments

    Not recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Czechia Finland France Hungary Ireland +4
  • Study Comparing Repotrectinib and Crizotinib for Patients with Advanced or Metastatic ROS1-positive Non-Small Cell Lung Cancer

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Austria France Germany Greece Hungary Italy +4
  • Study on Patient Preference for Nivolumab and Relatlimab Administration Methods in Melanoma Patients

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Greece Italy Spain
  • Study of BMS-986158 Alone and with Ruxolitinib or Fedratinib for Patients with Intermediate or High Risk Myelofibrosis

    Not recruiting

    1 1 1 1
    Investigated diseases:
    France Germany Greece Italy Poland Romania +1
  • Study of BMS-986466 with Adagrasib and Cetuximab for Patients with KRAS G12C-mutant Advanced Solid Tumors

    Not recruiting

    1 1 1 1
    Belgium Finland France Italy Spain